Decheng Capital LLC Equillium, Inc. Call Options Transaction History
Decheng Capital LLC
- $326 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding EQ
# of Institutions
28Shares Held
11.5MCall Options Held
38.1KPut Options Held
0-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$4.14 Million1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA842KShares$783,0110.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$522,9181.37% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny300KShares$279,3720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA216KShares$201,0690.0% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $31.9M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...